Sudden sensorineural hearing loss associated with vardenafil

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 112-

  Snodgrass, Amanda J ^a   Campbell, Heather M ^a   Mace, David L ^a   Faria, Victoria L ^b   Swanson, Kathleen M ^a   Holodniy, Mark ^b,c  

^a University of New Mexico   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug reactions; Drug safety; PDE 5; Phosphodiesterase type 5 inhibitors; SSHL; Sudden sensorineural hearing loss; Vardenafil

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATENOLOL; COTRIMOXAZOLE; DEXAMETHASONE; GEMFIBROZIL; GLIPIZIDE; GLUCOSE; LISINOPRIL; LOPINAVIR PLUS RITONAVIR; PREDNISONE; TENOFOVIR; VARDENAFIL;

ADULT; ADVERSE OUTCOME; ARTICLE; AUDIOGRAPHY; CASE REPORT; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; EMERGENCY WARD; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; HYPERTENSION; LENGTH OF STAY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT; PERCEPTION DEAFNESS; PROBABILITY; RATING SCALE; VIRUS LOAD;

EID: 84878120975     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1592/phco.30.1.112     Document Type: Article

References (19)

1. Byl F. Sudden hearing loss: eight years experience and suggested prognostic table. Laryngoscope 1984;94:647-61.
2. Leong AC, Fairley JW, Padgham ND. Sudden hearing loss. Clin Otolaryngol 2007;32:391-4.
3. Mattox D, Simmons F. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:463-80.
4. Hong BN, Yi TH, Kim SY, Kang TH. High-dosage sildenfil induces hearing impairment in mice. Biol Pharm Bull 2008;31:1981-4.
5. Kamel A, Khaouli R, Saha M, Al Mitwally K, Fouad W, Landen H. The real life safety and efficacy of vardenafil. Clin Drug Invest 2007;27:339-46.
6. U.S. Food and Drug Administration. FDA uudats labeling for Viagra. Cialis, and Levita for rare post-marketing reports of eye problems. July 8, 2005. Available from http://ww.fda.gov/bbs/topics/NEW/2005/NEW01201.htmal. Accessed Decemeber 19, 2007.
7. U.S. Food and Drug Administration. Infromation for healthcar professionals: sildenafil (marketed as Viagra and Revatio), vardenfil (marketed ad Levitra, tadalafil (marketed as Cialis). November 14, 2007. Available from http://www.fda.gov/eder/drug/InfoSheets/HCP/ED-HCP.htm. Accessed Devember, 19, 2007.
8. Mukherjee B, Shivakumar T. A case of sensorinerual deafness following ingestiong of sildenfil. J Laryngol Otal 2007;121:395-7.
9. U.S. Food and Drug Administration. FDA announces revisions to labels for Cialis, Levitra, and Vaigra. October 18, 2007. Available from http://www.fda.gov/bbs/topics/NEWS/2007/NEW01730.html. Accessed December 19, 2007.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probablity for adverse drug reactions. Clin Pharmacol Ther 1981;20:239-45.
11. Importence-Guide.com. A comprehensive guide to Uprima. Available from http://www.inpotence-guide.com/uprima.html. Accessed February 15, 2008.
12. Department of Vaterans Affairs Employee Education System. Vietnam veterans and Agent Orange exposure. March 2002. Available from http://www1.va.gov/agentorange/docs/VHIagentorange.pdf. Accessed January 15, 2008.
13. Department of Veterans Affairs. Agent Orange review, vol 6, no.1. October 1988. http://www1.va.gov/agentorange/docs/Oct88v6-1.PDF. Accessed February 28, 2008.
14. Simdon J, Water D, Bartlett S, Connick E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inlibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis 2001;32:1623-7.
15. Wilaims B, Ototoxicity may be assocaiated with protease inhibitor therapy. Clin Infect Dis 2001;33:2100-2.
16. Reffelmann T, Kloner R, Vardenfil: a selective inhibitor of phosphodiestenrase-5 for the treatment of erectile dsfunction. Expert Opin Pharmacother 2007;8:965-74.
17. McNicholl IR. Durg interactions among the antiretrovirals. Curr Inf Dis Rep 2004;6:159-62.
18. Morris MS, Prasad S. Otologic disease in the acquired immunodeficiency syndrome. Ear Nose Throat J 1990;69:451-3.
19. Real R, Thomas M, Gerwin J. Sudden hearing loss and acquired immunodeficiency syndrome. Otolaryngol Head Neck Surg 1987;97:490-12.